# Clinical Trials Data KRAS - Document 24

# Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

## Clinical Trial: https://clinicaltrials.gov/study/NCT02039336

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histological or cytological proof of advanced non-small cell lung cancer\n\* Written documentation of KRAS (exon 2, 3 or 4) mutation\n\* At least 18 years of age or older\n\* Able and willing to give written informed consent\n\* WHO performance status of 0 or 1\n\nExclusion Criteria:\n\n\* Symptomatic or untreated leptomeningeal disease\n\* Symptomatic brain metastasis\n\* Impairment of gastrointestinal function\n\* Uncontrolled infectious disease\n\* Left ventricular ejection fraction \\< 50%\n\* Retinal degenerative disease or with history of uveitis, retinal vein occlusion or retinal detachment\n\nOther protocol-defined inclusion/exclusion criteria may apply",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with a KRAS gene mutation (specifically in exon 2, 3, or 4) would be \*potentially\* eligible for this trial. The inclusion criteria explicitly state "Written documentation of KRAS (exon 2, 3 or 4) mutation".  
  
However, it's crucial to note the phrase "Other protocol-defined inclusion/exclusion criteria may apply." This means there could be additional requirements or disqualifying factors not listed in this summary. The patient would need to be fully evaluated by the study team to determine definitive eligibility.